

Company Registration No. 06514054 (England and Wales)

**CAS CLIFTON HEALTHCARE LIMITED**  
**ANNUAL REPORT AND FINANCIAL STATEMENTS**  
**FOR THE YEAR ENDED 31 DECEMBER 2021**

FRIDAY



\*ABD5JHC2\*

A25

23/09/2022

#41

COMPANIES HOUSE

# CAS CLIFTON HEALTHCARE LIMITED

## COMPANY INFORMATION

---

<b>Directors</b>	Dr Antonio Romero Mr Mark Ground Mr Michael McQuaid Mr Thomas Day
<b>Secretary</b>	Ms Katie Bowen
<b>Company number</b>	06514054
<b>Registered office</b>	Nepicar House London Road Wrotham Heath Sevenoaks Kent England TN15 7RS
<b>Accountant</b>	PricewaterhouseCoopers LLP 1 Embankment Place London WC2N 6RH

---

# **CAS CLIFTON HEALTHCARE LIMITED**

## **CONTENTS**

---

	<b>Page(s)</b>
Directors' report	1 - 3
Income statement	4
Statement of financial position	5
Statement of changes in equity	6
Notes to the financial statements	7

---

# CAS CLIFTON HEALTHCARE LIMITED

## DIRECTORS' REPORT

### FOR THE YEAR ENDED 31 DECEMBER 2021

---

The directors present their annual report and financial statements for the year ended 31 December 2021.

#### Results and dividends

The results for the year are set out on page 4.

The company did not trade in the current year or the preceding year. No ordinary dividends were paid during the year (2020: £nil). The directors do not recommend payment of a final dividend (2020: £nil).

#### Directors

The directors who held office during the year and up to the date of signature of the financial statements were as follows:

Dr Antonio Romero

Mr Mark Ground

Mr Michael McQuaid

Mr Gerald Corbett

Mr Thomas Day

(Resigned 19 July 2021)

(Appointed 30 July 2021)

#### Qualifying third party indemnity provisions

The company has made qualifying third party indemnity provisions for the benefit of its directors which were made during the year and remain in force at the reporting date.

#### Financial and business risk management

The group's activities expose it to a variety of financial risks that include market and external risks, liquidity risk, interest rate risk, credit risk and data risk:

#### Market and external risks

The business operates in a highly competitive market. Most competition is based on local catchment areas and the funding body's procurement initiatives with the NHS and Local Authorities. Our business continues to be supported by strong relationships with customers, and we continue to work with our regulators aiming to be the market leader in our sector in delivery of clinical quality.

Cygnat monitors competition closely to ensure that it remains competitive in the market place. We are pleased to be partnering with our commissioners on working together in new innovative ways, and we continue to invest in capital expenditure to maintain existing sites, and to develop further capacity.

Cygnat manages the risk associated with demand fluctuations by offering diversified services and monitoring demand, converting unused capacity to alternative services when appropriate. Cygnat monitors prices charged both internally and externally to ensure that its services are appropriately priced to compete and provide value for customers.

At Cygnat as the effects of COVID-19 are clear our focus continues to be keeping those in our care, and our staff as protected and safe as possible. We have very dedicated teams who are closely tracking the situation and its recovery. Our teams meet every day, from Ward to Board, to help ensure business continuity and adaptation to the evolving situation.

Cygnat is informed of government guidance and able to respond to the guidance as it changes. Our priority is to make sure we can provide safe continued care. We are working closely with our business partner, the NHS.

# **CAS CLIFTON HEALTHCARE LIMITED**

## **DIRECTORS' REPORT (CONTINUED)**

**FOR THE YEAR ENDED 31 DECEMBER 2021**

---

### ***Liquidity risk***

Cygnit relies on publicly funded entities in the UK such as the NHS, Clinical Commissioning Groups (CCGs) and Local Authorities for substantially all of its revenues and the loss or reduction of such funding, or changes in procurement methods, could negatively impact the company's occupancy rates which could have corresponding material adverse effects on liquidity.

The Group monitors cash flow to ensure it has sufficient available funds for operations and planned expansions, and adapts its service provision depending on what is required. Cygnit is supported by its long term strategic partner Universal Health Services Inc. ("UHS"), the leading provider of behavioural health care in the USA.

### ***Interest rate risk***

Other than funding from its strategic partner Universal Health Services Inc., the group has no other external funding attracting interest, and therefore has limited exposure to interest rate risk.

### ***Credit risk***

The Group has limited credit risk, as the majority of income is due from the NHS, Local Authorities and CCG's.

### ***Data risk***

The security and availability of operational data is essential and system security hardware and software are used to achieve this.

Cygnit takes its data protection responsibilities very seriously and is committed to operating within the necessary regulatory boundaries of the data protection legislation. Cygnit is aware of the requirements and is keeping its data protection and governance practices up to date accordingly.

Cygnit continued to invest its cash flow in operational infrastructure, its IT and systems infrastructure.

### ***Going concern***

The financial statements have been prepared on a going concern basis which the Directors believe to be appropriate for the reasons set out below. The Directors have a reasonable expectation that the Company has adequate resources to continue in operational existence for the foreseeable future. The Company is in a net current asset and net asset position.

The directors have received a letter from Cygnit Health UK Limited indicating their intention to: (1) continue to provide the financial resources necessary to support the company in meeting its liabilities as and when they fall due for a period of at least one year from the date of signing of the company's financial statements for the year ended 31 December 2021; and (2) not to require settlement of outstanding intercompany balances to the extent that money is not, at the relevant settlement date, otherwise available to the company to meet such liabilities for a period of at least one year from the date of signing of the company's financial statements for the year ended 31 December 2021. As with any company placing reliance on other group entities for financial support, the directors acknowledge that there can be no certainty that this support will continue although, at the date of approval of these financial statements, they have no reason to believe that it will not do so and they have reviewed the consolidated group cash flow forecasts for the entity providing the letter of support extending 12 months from signing date and have concluded there are adequate resources to support the company as a going concern as well as all other subsidiaries to whom support is being provided for this period.

### ***Future developments***


The company has taken advantage of the disclosure exemption in accordance with the special provisions relating to small companies within Part 15 of the Companies Act 2006.

# CAS CLIFTON HEALTHCARE LIMITED

## DIRECTORS' REPORT (CONTINUED)

FOR THE YEAR ENDED 31 DECEMBER 2021

The directors' report was approved by the Board of Directors on 3rd AUGUST and signed on its behalf by  
2022



Dr Antonio Romero

Director

Date: 3/8/2022



Mr Mark Ground

Director

Date: 3/8/2022

Nepicar House  
London Road  
Wrotham Heath  
Sevenoaks  
Kent  
TN15 7RS

## **CAS CLIFTON HEALTHCARE LIMITED**

### **INCOME STATEMENT**

***FOR THE YEAR ENDED 31 DECEMBER 2021***

---

During the current and preceding period, the company did not trade and received no income and incurred no expenditure.

Consequently, during these periods the company made neither a profit nor a loss. Furthermore there were no items of other comprehensive income in either period.

The accompanying notes on page 7 form part of the financial statements.

# CAS CLIFTON HEALTHCARE LIMITED

## STATEMENT OF FINANCIAL POSITION

AS AT 31 DECEMBER 2021

	Note	2021 £	2020 £
<b>Current assets</b>			
Cash and cash equivalents		<u>1</u>	<u>1</u>
<b>Total assets less current liabilities</b>		<u>1</u>	<u>1</u>
<b>Net assets</b>		<u>1</u>	<u>1</u>
<b>Equity</b>			
Called up share capital	1	<u>1</u>	<u>1</u>
<b>Total equity</b>		<u>1</u>	<u>1</u>

The company has been dormant throughout 2020 and 2021 and as such there has been no comprehensive income or changes in equity in either year.


For the year ended 31 December 2021 the company was entitled to exemption under section 480 of the Companies Act 2006 relating to dormant companies.


The members have not required the company to obtain an audit in accordance with section 476 of the Companies Act 2006.

The directors acknowledge their responsibilities for complying with the requirement of the Act with respect to accounting records and the preparation of financial statements.

These financial statements have been prepared in accordance with the provisions applicable to companies subject to the small companies regime.

The financial statements on pages 4 to 7 were approved by the Board of Directors on 3rd AUGUST and signed on its behalf by: 2022

  
Dr Antonio Romero  
Director

  
Mr Mark Ground  
Director

Company Registration No. 06514054



# **CAS CLIFTON HEALTHCARE LIMITED**

## **STATEMENT OF CHANGES IN EQUITY**

***FOR THE YEAR ENDED 31 DECEMBER 2021***

---

	Share capital £
<b>Balance at 1 January 2020</b>	1
<b>Year ended 31 December 2020:</b>	
Result and total comprehensive income for the year	-
	<hr/>
<b>Balance at 31 December 2020</b>	1
<b>Year ended 31 December 2021:</b>	
Result and total comprehensive income for the year	-
	<hr/>
<b>Balance at 31 December 2021</b>	1
	<hr/> <hr/>

# CAS CLIFTON HEALTHCARE LIMITED

## NOTES TO THE FINANCIAL STATEMENTS

### FOR THE YEAR ENDED 31 DECEMBER 2021

---

<b>1</b>	<b>Share capital</b>	<b>2021</b>	<b>2020</b>
		<b>£</b>	<b>£</b>
	<b>Called up share capital</b>		
	<b>Authorised, issued and fully paid</b>		
	1 Ordinary share (2020: 1) of £1 each	1	1
		<u>1</u>	<u>1</u>

#### **2 Controlling party**

The largest group in which the results of the company are consolidated is that headed by Universal Health Services Inc., a company incorporated in the US. The smallest in which they are consolidated is headed by Cygnet Health UK Limited. The consolidated financial statements of these groups are available to the public. Universal Health Services Inc. financial statements may be obtained from <http://www.uhsinc.com/> and Cygnet Health UK Limited financial statements may be obtained from:

Nepicar House  
London Road  
Wrotham Heath  
Sevenoaks  
Kent, TN15 7RS